# US 2006/0154933 A1 · Inhibitors of Cdc25 phosphatases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154933 A1
- Document ID: US20060154933A1
- Status: Published application
- Kind: A1
- Application number: 11/350,692
- Filed: 2006-02-09
- Published: 2006-07-13
- Earliest claimed: 2000-07-28
- Assignees: Scras
- Inventors: Gregoire Prevost; Marie-Christine Brezak Pannetier; Marie-Odile Galcera Contour; Christophe Thurieau; Francoise Gramatica; Bernard Ducommun; Christophe Lanco
- Web page: https://patentgrep.com/patent/US20060154933A1

## CPC

- C07D 295/26: Sulfur atoms
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/381: having five-membered rings
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61P 17/14: for baldness or alopecia
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 217/84: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C 229/36: with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- C07C 235/66: with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/13: the carbon skeleton containing six-membered aromatic rings
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/37: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 233/84: Sulfur atoms
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/192: from aromatic carboxylic acids
- C07D 333/22: Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
- C07D 333/34: Sulfur atoms
- C07F 9/12: with hydroxyaryl compounds
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method of inhibiting cdc25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method of inhibiting cdc 25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of the formula
wherein A is
wherein two of R1, R2, R3, R4, and R5 are hydrogen and the other three are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio and —NR6R7, it being understood that:
either R1 and one of R2 and R4 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or R2 and one of R3 and R5 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or R4 and one of R3 and R5 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or also one of R1, R3 and R5 is selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7, and B—N(W)—X—Y remainder is attached to A by nitrogen, R6 and R7 are independently each time that they occur a hydrogen or alkyl or R6 and R7 together with the nitrogen atom form a heterocycle of 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being independently selected from the group consisting of —CR8R9—, —O—, —S— and —NR10—, R8 and R9 independently are each time that they occur selected from the group consisting of hydrogen, alkyl, alkoxy, benzyloxycarbonylamino and dialkylamino, and R10 independently is each time that it occurs hydrogen or alkyl,
wherein either R11 and one of R13, R14 and R15 are hydroxy while R13, R14 and R15 as well as R16 are hydrogen,
or R12 and R16 are hydroxy while R11, R13, R14 and R15 are hydrogen;
B is —(CH2)p—, p is an integer from 0 to 1;
W is hydrogen or alkyl;
X is selected from the group consisting of 4CH2)q—, —(CH2)q—NH and —CO—(CH2)r—, q is an integer from 1 to 6 and r is an integer from 0 to 6;
or B—N(W)—X—Y is
wherein B is as defined above, t is an integer from 0 to 2, s is an integer from 0 to 1 and R17 and R18 are independently hydrogen or alkyl;
and:
when X is —CH2)q— or —CO—(CH2)r—, then Y is
wherein R19 is selected from the group consisting of hydrogen, halogen, nitro, alkyl, alkylthio, —NR21R22, —SO2—NR22R24, —NH—SO2—R25 and —O—P(O)(OR26)(OR)27, R21 and R22 independently are hydrogen or alkyl,
R23 and R24 independently are hydrogen or alkyl, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 7 ring members, the additional members are independently selected from the group consisting of —CHR28—, —NR29—, —O— and —S—, R28— and R29 are independently each time that they occur, hydrogen or alkyl,
R25 is selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, the aryl or heteroaryl nucleus of which is optionally substituted by at least one member independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxy, alkoxy and nitro, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are alkyl,
R26 and R27 are independently alkyl,
and R20 is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy and alkylthio,
when X is 4CH2)q—NH— or when B—N(W)—X—Y is
then Y exclusively is —SO2—R30 wherein R30 is selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, the aryl or heteroaryl nucleus of which is optionally substituted by at least one member independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxy, alkoxy and nitro, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are alkyl;
it being understood that when B—N(W)—X—Y is
then B is —CH2)—;
or a pharmaceutically acceptable salt thereof sufficient to inhibit cdc25 phosphatases.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
A is
wherein two of R1, R2, R3, R4 and R5 are hydrogen and the other three are independently selected from the group consisting of hydrogen, halogen, alkyl, alkylcarbonyloxy, hydroxy, alkoxy and NR6R7, it being understood that:
either R1 and one of R2 and R4 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or R2 and one of R3 and R5 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or R4 and one of R3 and R5 are independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7,
or one of R1, R3 and R5 is independently selected from the group consisting of hydroxy, alkylcarbonyloxy and —NR6R7, and B—N(W)—X—Y remainder is attached to A by nitrogen,
R6 and R7 are independently each time that they occur, hydrogen or alkyl or R6 and R7 together with the nitrogen atom form a heterocycle with 5 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being independently selected from the group consisting of CR8R9—, —O—, —S—, and —NR10—[radical], R8 and R9 independently each time that they occur hydrogen or alkyl or alkoxy, and R10 independently is each time that it occurs hydrogen or alkyl,
or A is
wherein
either R11 and one of R13, R14 and R15 is hydroxy while the other R13, R14 and R15 as well as R16 are hydrogen,
or R12 and R16 are hydroxy while R11, R13, R14 and R15 are hydrogen;
B is —CH2)p, p is an integer from 0 to 1;
W is hydrogen or alkyl;
X is selected from the group consisting of —(CH2)q—, —(CH2)q—NH— and —CO—(CH2)r, q is an integer from 1 to 4 and r is an integer from 0 to 5;
or B—N(W—X—Y is
wherein B is as defined in claim 18, t is an integer from 0 to 2, s is an integer from 0 to 1, R17 and R18 are independently hydrogen or alkyl;
when X is —CH2)q— or —CO—(CH2)r—, Y is
wherein R19 is hydrogen, halogen, nitro, alkyl, alkylthio, —NR21R22, —SO2—NR23R24, —NH—SO2— —R25 and —O—P(O)(OR26)(OR27),
R21 and R22 independently are hydrogen or alkyl, R23 and R24 independently are hydrogen or alkyl, or R23 and R24 together with the nitrogen atom which carries them form a heterocycle with 5 to 6 ring members, the additional members of which are independently selected from the group consisting of —CHR28—, —NR29—, —O— and
—S—, R28 and R29 are independently each time that they occur, hydrogen or alkyl,
R25 is alkyl or aryl optionally substituted by at least one member selected from the groups consisting of halogen, alkyl, haloalkyl, alkoxy and nitro, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are alkyl,
R26 and R27 are independently alkyl,
and R20 is hydrogen or alkyl or akoxy,
when X is a —CH2)q—NH— or B—N(W)—X—Y is
then Y is —SO2—R30, R30 is selected from the group consisting of alkyl haloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl the aryl or heteroaryl nucleus of which is optionally substituted by at least one member independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy and nitro, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are alkyl.

### Claim 20 (depends on 18)

The method of claim 18, wherein the compound is selected from the group consisting of:
-4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
-4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
-4-(dimethylamino)-2-methoxy-6-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
-4-(dimethylamino)-2-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
-2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}-methyl)phenol;
-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
-4-(dimethyl amino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}-methyl)phenyl acetate;
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 18)

The method of claim 18 wherein Y is not (T) and the condition to be treated is selected from the group consisting of prostate cancer, pancreatic cancer, breast cancer, lymphoma and head and neck cancer.

### Claim 22 (depends on 18)

The method of claim 18 wherein Y is (T), and the condition being treated is spontaneous alopecia, alopecia induced by exogenous products, or radiation-induced alopecia.
